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Background: Mitochondrial diseases, a group of multi-systemic disorders often characterized by tissue-speciﬁc
phenotypes, are usually progressive and fatal disorders resulting from defects in oxidative phosphorylation.
MTO1 (Mitochondrial tRNA Translation Optimization 1), an evolutionarily conserved protein expressed in high-
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T
Ketogenic diet
Mitochondrial translation optimization 1
Oxidative Phosphorylation Defect
energy demand tissues has been linked to human early-onset combined oxidative phosphorylation deﬁciency
associated with hypertrophic cardiomyopathy, often referred to as combined oxidative phosphorylation deﬁ-
ciency-10 (COXPD10).
Material and methods: Thirty ﬁve cases of MTO1 deﬁciency were identiﬁed and reviewed through international
collaboration. The cases of two female siblings, who presented at 1 and 2 years of life with seizures, global
developmental delay, hypotonia, elevated lactate and complex I and IV deﬁciency on muscle biopsy but without
cardiomyopathy, are presented in detail.
Results: For the description of phenotypic features, the denominator varies as the literature was insuﬃcient to
allow for complete ascertainment of all data for the 35 cases. An extensive review of all known MTO1 deﬁciency
cases revealed the most common features at presentation to be lactic acidosis (LA) (21/34; 62% cases) and
hypertrophic cardiomyopathy (15/34; 44% cases). Eventually lactic acidosis and hypertrophic cardiomyopathy
are described in 35/35 (100%) and 27/34 (79%) of patients with MTO1 deﬁciency, respectively; with global
developmental delay/intellectual disability present in 28/29 (97%), feeding diﬃculties in 17/35 (49%), failure
to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%).
There are 19 diﬀerent pathogenic MTO1 variants identiﬁed in these 35 cases: one splice-site, 3 frameshift and 15
missense variants. None have bi-allelic variants that completely inactivate MTO1; however, patients where one
variant is truncating (i.e. frameshift) while the second one is a missense appear to have a more severe, even fatal,
phenotype. These data suggest that complete loss of MTO1 is not viable. A ketogenic diet may have exerted a
favourable eﬀect on seizures in 2/5 patients.
Conclusion: MTO1 deﬁciency is lethal in some but not all cases, and a genotype-phenotype relation is suggested.
Aside from lactic acidosis and cardiomyopathy, developmental delay and other phenotypic features aﬀecting
multiple organ systems are often present in these patients, suggesting a broader spectrum than hitherto reported.
The diagnosis should be suspected on clinical features and the presence of markers of mitochondrial dysfunction
in body ﬂuids, especially low residual complex I, III and IV activity in muscle. Molecular conﬁrmation is required
and targeted genomic testing may be the most eﬃcient approach. Although subjective clinical improvement was
observed in a small number of patients on therapies such as ketogenic diet and dichloroacetate, no evidence-
based eﬀective therapy exists.
1. Introduction
Mitochondrial diseases encompass a broad range of disorders that
may result from pathogenic mutations of mitochondrial DNA or the
nuclear genome and aﬀect all ages in a mono- or multisystemic
manner with an estimated prevalence of ~1:5,000 [1,2]. Approxi-
mately 1200 diﬀerent nuclear genes encode mitochondrial proteins
and causal defects have been identiﬁed in ~300 genes, many
through genome wide sequencing approaches [3,4]. Continued
identiﬁcation of nuclear genes associated with mitochondrial disease
will result in a greater understanding of mitochondrial homeostasis
and function [5].
A novel form of mitochondrial disease caused by mutations in
MTO1, encoding the mitochondrial tRNA translation optimization 1
(MTO1) protein (OMIM#614667) was ﬁrst described in 2012 in 2
Italian siblings, born of unrelated parents, presenting soon after birth
with lactic acidosis, severe hypoglycaemia and fatal infantile hy-
pertrophic cardiomyopathy [6,7]. MTO1 is one of two subunits of an
enzyme that catalyzes the 5-carboxymethylaminomethylation of the
wobble uridine base in the mitochondrial tRNAs speciﬁc to leucine,
tryptophan, glutamine, glutamic acid and lysine [8–10]. This post-
transcriptional modiﬁcation is critical to the accuracy and eﬃciency
of mtDNA translation. As is observed with other nuclear-mitochon-
drial diseases of mt-tRNA modiﬁcation such as TRIT1, TRMT5,
GTPBP3 and PUS1, MTO1 deﬁciency usually results in a combined
reduction of mtDNA-dependent respiratory chain activities
[6,11–14].
Hallmark features of MTO1 deﬁciency include hypertrophic cardi-
omyopathy (HCM), lactic acidosis (LA) and mild to severe global de-
velopmental delay (GDD)/intellectual disability (ID) [6,15] but sig-
niﬁcant phenotypic heterogeneity exists. Two female siblings with
MTO1 mitochondriopathy who remain without CM at the adolescent
age are presented in detail in this paper. A mouse model of the MTO1
deﬁciency was recently generated, and shown to have similar to human
phenotype [16]. Using the mouse embryonic ﬁbroblasts from the
MTO1-deﬁcient mice, it was recently demonstrated that MTO1 controls
mitochondrial translation rate via mt-tRNA modiﬁcation in a tissue-
speciﬁc manner [11]. This explains the organ speciﬁc pathologies and
the reported phenotypic heterogeneity. The aim of this study was to
review and report on 35 cases of MTO1-deﬁcient mitochondrial disease,
outlining their clinical and molecular features, response to treatment
and genotype-phenotype evaluation.
2. Cases and methods
2.1. Clinical descriptions
Two female siblings and their parents were enrolled into the
Treatable Intellectual Disability Endeavour eXome (TIDEX) neuro-
metabolic discovery study (UBC IRB approval H12-00067) [17].
Written consent for data and sample collection, whole exome se-
quencing (WES), as well as publication of the current case reports
was provided by the parents. Consent for publication of the other
cases mentioned in the tables was provided to the clinician or la-
boratory scientist at the respective institutions. These naturally
conceived children were born to non-consanguineous parents of
Caucasian (paternal) and Malayo-Polynesian ethnicity (maternal).
Family history was signiﬁcant for a maternal uncle with ID, a ma-
ternal aunt and ﬁrst cousin with a history of febrile seizures, and a
maternal ﬁrst cousin with speech delay and hyperactivity.
Case 1: this 16-year-old female presented with early onset mild
developmental delay and atypical febrile seizure at 2.5 years with
subsequent absence seizures at 3.5 years. She was born at 38 weeks
gestation, by spontaneous vaginal delivery, weighing 3.34 kg. She sat
unsupported at 8 months of age and started to cruise at 12 months.
First concerns were raised with speech delay (ﬁrst words were at
2 years). Physical exam at age 4 years showed hypotonia with mod-
erate delay in gross motor, ﬁne motor, expressive language
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(approximately 100 words) and social skills. Plasma and CSF lactate
levels were elevated at 4.4 mmol/L (ref range: 0.5–2.2 mmol/L) and
3.3 mmol/L respectively. Plasma amino acids demonstrated in-
creased alanine of 657 μmol/L (reference range 148–475 μmol/L).
Respiratory chain analysis on muscle biopsy showed complex I and
IV deﬁciency (complex I activity: 4.1 nmol/min/mg (ref range
17.9–56.7); complex IV activity: 0.76 nmol/min/mg (ref range
2.3–5.03)). Pathological analysis of the muscle demonstrated a
greater number of type 1 than type 2 ﬁbres with variation in ﬁbre
size diameter but no histological, histochemical or ultrastructural
features to suggest a mitochondrial myopathy. She was commenced
on oral L-carnitine, thiamine and riboﬂavin, with coenzyme q10,
vitamin E, and vitamin D added later.
At age 6 years, the patient was ataxic with generalized muscle
weakness, was unable to ride a tricycle, and could only make 2–3
word sentences. She experienced behavioural change with the onset
of aggressiveness and pica. At 7 years a ketogenic diet was started
(highest ratio 4.75:1) which initially reduced her seizure activity, but
six months after commencement, in the context of a severe ﬂu-like
illness, she developed a sudden reduction in bilateral visual acuity
(10/400), ptosis and generalised weakness. Fundoscopy demon-
strated bilateral optic disk pallor, localized to the papillomacular
bundle. MRI brain was normal at 3 and 8 years, but at age 9 years a
signal abnormality in the midline of the brain and in the optic chiasm
was detected on T2 imaging. At 11 years she presented in status
epilepticus and CT/MRI brain imaging demonstrated multiple areas
of hyperintense T2/FLAIR signal within the cerebral peduncles, basal
ganglia and cortex most likely due to a metabolic crisis which had
largely resolved one week later. Seizures proved refractory to treat-
ment and the ketogenic diet was reduced to a 2:1 ratio at age
12 years. This was followed by an improvement of her visual acuity
and subjective energy levels.
The phenotype evolved and assessment at 16 years of age showed
moderate ID requiring a special life skills program in school, optic
neuropathy with good visual acuity in both eyes, bilateral ptosis,
mild facial weakness, myopathic ataxia with mild dysmetria with
intention tremor and dysarthria with decreased muscle mass and
proximal muscle strength but without bulbar symptoms and con-
stipation. Echocardiography (ECHO) was unremarkable at age
15 years. Short stature between ages 8 to 15 years (height less than
3rd centile and weight on the 3rd centile), prompted an en-
docrinology work-up which showed no evidence of hormonal ab-
normalities and at 16 years her height and weight were normal
(3rd–10th centile). Head circumference remained normal (between
mean and +1 SD). The patient’s seizures were poorly controlled and
she continued to have up to 40 seizures per week on a ketogenic diet
(2:1), levetiracetam, piracetam, clonazepam and ruﬁnamide which
varied from generalized, absence, to drop seizures. Hearing assess-
ment was normal.
Case 2 is a 12-year-old full female sibling who presented with a
similar albeit milder phenotype, with febrile seizures at 19 and
26 months and subsequently developed afebrile seizures. She was
born at 40 weeks gestation, by spontaneous vaginal delivery,
weighing 3.85 kg. During the pregnancy, maternal gestational dia-
betes was present which required insulin from 7 months gestation. At
3.5 years elevated plasma lactate (3.2–4.2 mmol/L; ref range
0.5–2.2 mmol/L) and alanine (711 μmol/L; ref range 148–475 μmol/
L) were noted. At 3 years the patient was considered devel-
opmentally appropriate but at 4.5 years she required aid in pre-
school. She was dysarthric with generalized weakness, and tended to
trip when walking. At 4 years she started on oral riboﬂavin,
coenzyme Q10, L-carnitine. Cranial MRI/spectroscopy and electro-
myography/nerve conduction studies were normal. Respiratory
chain analysis on muscle biopsy showed complex I and IV deﬁ-
ciencies (complex I activity – 11.3 nmol/min/mg (ref range
17.9–56.7) and complex IV- 02.16 nmol/min/mg (ref range
2.3–5.03)). Pathology, including histochemistry and electron mi-
croscopy was normal.
Ophthalmological and audiological exams as well as ECHO were
normal at 5 and 12 years respectively. At 12 years, she showed mod-
erate ID and attended mainstream school with an adapted program. She
had normal muscle strength in her face and limbs with mild hypotonia
and no bulbar symptoms. Her deep tendon reﬂexes were normal. Her
seizures varied and were well controlled with clobazam, levetiracetam,
lamotrigine and ethosuximide. Hence the modiﬁed Atkins diet was not
attempted. Growth parameters were consistently normal with height
and weight between the 90th–95th centile and her head circumference
between 25th–50th centile. For a clinical summary of these two cases
see patient numbers 4 and 5 of Table 1.
2.2. Whole exome sequencing for the two presented siblings
Quad-WES analysis (index-aﬀected sibling-unaﬀected mother-un-
aﬀected father) using the Agilent SureSelect kit and Illumina HiSeq
2000 (Perkin-Elmer, USA) was performed. The data was analysed using
our semi-automated bioinformatics pipeline [17]: (1) the sequencing
reads were aligned to the human reference genome version hg19 using
Bowtie 2 [18], (2) the duplicates were marked and sorted using Picard,
(3) variants were called using SAMtools and BCFtools after indel rea-
lignment using GATK, (4) transcripts were annotated using snpEﬀ [19],
(5) functional variants were prioritized for rare variants by comparison
against the public databases [dbSNP, NHLBI Exome Sequencing Project
Exome Variant Server, and Exome Aggregation Consortium (ExAC)]
and (6) subsequently screened under a series of Mendelian inheritance
models: homozygous, hemizygous, compound heterozygous and de
novo as described previously [20].
2.3. Identiﬁcation and review of 35 cases of MTO1 deﬁciency
Through a PubMed literature search (2012–2017) and direct contact
with clinical colleagues caring for mitochondrial diseases patients, we
identiﬁed and collected clinical and genotypic information on a further
33 patients (18 published and 15 unpublished) with pathogenic muta-
tions in MTO1. The data on the total of 35 patients were collated in
Excel. Statistical analysis was limited to descriptive and conﬁdence
interval calculations (https://www.pedro.org.au/english/downloads/
conﬁdence-interval-calculator/).
3. Results
3.1. WES analysis for the two female siblings and parents
Whole exome sequencing (WES) identiﬁed three candidate genes
(CDH23, C5orf42 and MTO1), all three with compound heterozygous
variants. Of these three candidate genes, the variants on chromosome
6 aﬀecting the MTO1 protein were deemed to be the best explanation
for the observed phenotype in the siblings. Both aﬀected siblings are
compound heterozygous (Supplementary Fig. 1) for two variants
(c.1451G > A; p.Arg484Gln) and (c.1273G > A; p.Gly425Arg) in
MTO1 (NM 012123.3; NP 036255) on chromosome 6 which are
predicted in silico to be damaging by all tested tools. One of the
variants, p.Arg484Gln, is novel and had not been observed in
J.J. O'Byrne et al. Molecular Genetics and Metabolism 123 (2018) 28–42
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analysed databases, including dbSNP (v.142), NHLBI ESP, in – house
or ExAC while the second variant, p.Gly425Arg, had been reported
once in the ExAC database (Table 2). Sanger sequencing conﬁrmed
segregation with disease according to the recessive inheritance
model, with carrier status in each parent.
3.2. Clinical phenotypic spectrum (Table 1 and Supplementary Table 1)
Despite best eﬀorts complete data for all cases was not possible to
ascertain which has resulted in a variation of the denominator from 35.
An overview of clinical features of the 35 patients (17 males and 18
females) from 11 diﬀerent countries (Austria, Canada, Croatia,
Germany, India, Italy, Pakistan, Turkey, Spain, Syria and the United
Kingdom) is presented in Table 1.
12/35 (34%) cases are oﬀspring to consanguineous parents. 15/34
(44%) presented in the ﬁrst 2 days of life. The average age of pre-
sentation was 10.2 months (range: day 1 to 8.0 years).
At the time of writing 12/35 (34%) patients were deceased with an
average age of death of 2.67 years (range: week 1 to 23 years). 8/17
(47%) of males passed away at an average age at death of 0.96 years
(week 1 to 3.25 years). 4/18 (22%) of females were deceased with an
average age at death of 6.1 years (7 months to 23 years). Of those
presenting clinically in the ﬁrst 2 days of life, 7 patients (47%) passed
away before the age of 2 years, suggesting a relationship between
earlier presentation and a poorer prognosis.
The most common clinical feature at initial presentation was
hypertrophic cardiomyopathy (HCM), present in 15/34 [44%; 95%
CI, 29–60%] cases which over time developed in 27/34 [79%; 95%
CI, 63–90%] cases. Of note one patient (patient no.12) developed
dilated CM which may have been HCM at an earlier stage. Hypotonia
was identiﬁed in 10/35 [29%; 95% CI, 16–45%] cases at presenta-
tion but it eventually occurred in 22/35 [63%; 95% CI, 46–77%]
cases. GDD/ID aﬀected 28/29 [97%; 95% CI, 83–99%] cases for
whom this information was available; one patient was described to
have normal scholastic performance at age 19 years. Failure to thrive
(FTT) was reported in 12/35 [34%; 95% CI, 21–51%] cases, and
feeding diﬃculties in 17/35 [49%; 95% CI, 33–64%] cases. Optic
atrophy occurred in 11/21 [52%; 95% CI, 32–72%] cases with
thinning of the retinal nerve ﬁbre layer documented in three of these
cases. Other ocular pathology noted in this case series included ex-
ternal ophthalmoplegia (1/20 cases), unilateral ptosis (1/20 cases)
and mild bilateral cataracts (1/20 cases). Seizures were not a fre-
quent initial symptom (only present in 5/35 [14%; 95% CI, 6–29%]
but developed over time in 12/35 [34%; 95% CI, 21–51%] cases.
Ataxia was diagnosed in 3/34 [9%; 95% CI 3–23%] cases at initial
presentation and during follow-up in 7/34 [21%; 95% CI, 10–37%].
Hepatic dysfunction was infrequent, present in 3/35 [9%; 95% CI,
3–22%]. Renal involvement was also infrequent (1/35 [3%; 95% CI
0.5–14%]). Renal dysfunction, present in patient 12 is thought to be
secondary to CM and poor perfusion.
All cases of MTO1 deﬁciency presented with a combination of the
above described clinical features. There was no documented history of
diabetes or ptosis and only one documented case of hypoglycaemia.
Cranial MRIs were reported normal in 6/20 patients in whom it was
performed [30%; 95% CI, 15–52%]. Documented abnormalities in the
14/20 [70%; 95% CI, 48–85%] cases included lesions of the basal
ganglia and cerebellar peduncles and hypoplasia of the corpus cal-
losum. An elevated lactate peak on brain scan was identiﬁed in 2/5
cases in whom spectroscopy was performed. (Table 1 and Supplemen-
tary Table 1)
3.3. Genotypic spectrum (Table 2)
In the 35 patients from 26 unrelated families, we identiﬁed 19
diﬀerent MTO1 (NM 012123.3; NP 036255) variants (7 published
and 12 unpublished): 15 missense, 3 frameshifts and one splice-siteTa
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Table 2
Overview of the genotypic data of patients with conﬁrmed MTO1 deﬁciency.
Patient no Nucleotide change Protein change Inheritance In silico prediction scores ExAC frequency
1 c.1451G > A
c.1273G > A
p.Arg484Gln
p.Gly425Arg
Compound heterozygous CADD (33)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (34)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.000008237
2 c.1451G > A
c.1273G > A
p.Arg484Gln
p.Gly425Arg
Compound heterozygous CADD (33)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (34)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.000008237
3 c.1222 A > T p.Ile408Phe Homozygous CADD (29.1)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
4 c.963 A > C
c.1429 C > T
p.Lys321Asn
p.Arg477Cys
Compound heterozygous CADD (24.4)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0
5 c.1261-5T > G
c.1430G > A
p.Val422Ilefs*18
p.Arg477His
Compound heterozygous CADD (10.5)
SIFT (NA; splice-site)
PolyPhen2(NA; splice-site)
CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.0002307
6 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
7 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
8 c.122T > G
c.1282G > A
p.Val41Gly
p.Ala428Thr
Compound heterozygous CADD (26.1)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 0.998)
CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.00005766
9 c.1282G > A
c.402_403delTA
p.Ala428Thr
p.Tyr134Terfs
Compound heterozygous CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
Frameshift
0.00005766
0.000008241
10 c.631-631delG
c.I282G > A
p.Gly211Aspfs*3
p.Ala428Thr
Compound heterozygous Frameshift
CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.00005766
11 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
12 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
13 c.122T > G
c.767A > G
c.1282G > A
p.Val41Gly
p.His256Arg
p.Ala428Thr
Compound heterozygous CADD (26.1)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 0.998)
CADD (10.27)
SIFT (TOLERATED; 0.097)
PolyPhen2(BENIGN; 0.000)
CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0
0.00005766
14 c.1282G > A
c.1858dup
p.Ala428Thr
p.Arg620Lysfs*8
Compound heterozygous CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
Frameshift
0.00005766
0
15 c.1282G > A
c.1858dup
p.Ala428Thr
p.Arg620Lysfs*8
Compound heterozygous CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
Frameshift
0.00005766
0
16 c.1282G > A p.Ala428Thr Homozygous CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00005766
17 Compound heterozygous
(continued on next page)
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Table 2 (continued)
Patient no Nucleotide change Protein change Inheritance In silico prediction scores ExAC frequency
c.1282G > A
c.1430G > A
p.Ala428Thr
p.Arg477His
CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00005766
0.0002307
18 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
19 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
20 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
21 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
22 c.1222A > T p.IIe408Phe Homozygous CADD (29.1)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
23 c.1273G > A
c.1417C > T
p.Gly425Arg
p.Arg473Cys
Compound heterozygous CADD (34)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.000008237
0
24 c.1273G > A
c.1417C > T
p.Gly425Arg
p.Arg473Cys
Compound heterozygous CADD (34)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.000008237
0
25 c.1390C > T
c.1430G > A
p.Arg464Cys
p.Arg477His
Compound heterozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.0002307
26 c.1390C > T
c.1430G > A
p.Arg464Cys
p.Arg477His
Compound heterozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.0002307
27 c.1430G > A
c.1450C > T
p.Arg477His
p.Arg484Trp
Compound heterozygous CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (34)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.0002307
0.0000165
28 c.1430G > A
c.1450C > T
p.Arg477His
p.Arg484Trp
Compound heterozygous CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (34)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.0002307
0.0000165
29 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
30 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
31 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
32 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
33 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
34 c.1436A > T p. Asp479Gly Homozygous CADD (31)
SIFT (DAMAGING;0.002)
PolyPhen2(PROBABLY DAMAGING; 0.998)
0.000008241
(continued on next page)
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(Table 2 and Fig. 1). Please note that for consistency and proper
genotype-phenotype comparisons, we re-annotated all variants, in-
cluding those previously published, according to the NM 012123.3
transcript. The missense variants aﬀect the conserved amino acids
located in the: FAD-binding domain (n = 1), insertion domain 2
(n = 1), GidA speciﬁc sequence motif (n = 5) and central helical
domain (n = 8) of the MTO1 [21]. All of the variants are extremely
rare and either not observed in the population databases or observed
at very low frequencies. All but two variants are predicted to be
damaging by in silico prediction tools (Table 2). Patient 13 was found
to have three rare variants in MTO1: p.(Ala428Thr) inherited from
father and p.(Val41Gly) and p.(His256Arg) both inherited from
mother. While the p.(Ala428Thr) and p.(Val41Gly) are predicted
damaging and have been described in other patients with MTO1
deﬁciency, the p.(His256Arg) variant inherited in cis with the p.
(Val41Gly) is predicted benign by tested tools and may not con-
tribute to the phenotype. In addition to p.(His256Arg), the splice-site
variant in patient 3 has lower than expected pathogenicity score and
the predicted eﬀect on splicing is currently being tested experimen-
tally.
Of the 35 patients, 17 are homozygous and 13 compound het-
erozygous for missense variants, four are compound heterozygous for
a missense and a frameshift variant and one is compound hetero-
zygous for a missense and a predicted splice-site variant (Fig. 1 and
Table 2). None of the patients have bi-allelic truncating variants (i.e.
frameshift) suggesting that complete loss of MTO1 is unlikely to be
viable in humans. To determine to what extent the MTO1 genotype
may correlate with the clinical presentation, we ﬁrst grouped the
patients according to the shared genotype. We observed that the four
patients from three unrelated families who are compound hetero-
zygous for the p.(Ala428Thr) variant and a frameshift variant appear
to have more severe presentation: earlier than average age of pre-
sentation of clinical features at 0.04 years and shorter than average
survival time at 0.24 years, further supporting the hypothesis that
residual MTO1 protein function is needed for survival. Beyond the
probands who are compound heterozygous for one truncating var-
iant, we also observed that probands homozygous for the p.
(Thr411Ile) variant tend to have more severe phenotype, while the
probands homozygous for the p.(Arg464Cys) variant tend to have
longer than average survival time.
3.4. Biochemical phenotypic spectrum (Table 3)
3.4.1. Clinical chemistry
The most frequent biochemical feature at initial presentation was
lactic acidosis, identiﬁed in 21/34 [62%; 95% CI, 45–76%] cases in
whom it was measured. Eventually, once tested it was present in all
patients, 35/35 (100%). The average recorded peak level of plasma
lactate of 13.6 mmol/L (range 3.4 to 57.8 mmol/L). An elevated plasma
alanine was documented in 21/24 [88%; 95% CI, 69–96%] cases with
the average recorded level of 1346 μmol/L (range 630–6560 μmol/L).
Markers of mitochondrial dysfunction, including lactate, ketones, TCA
(Krebs cycle) metabolites, tyrosine metabolites, dicarboxylic acids and
3-methylglutaconate, were eventually present in the urinary organic
acid proﬁle in various patterns in every patient analyzed (14/14 [100%;
95% CI, 78–100%]) and CSF lactate was elevated in 5/6 cases [83%;
95% CI, 43–97%].
3.4.2. Respiratory chain analysis
Respiratory chain enzyme (RCE) analysis in muscle was performed
in 30 patients. Complex IV was deﬁcient in 28/30 cases and 27/30
cases showed evidence of combined deﬁciency. Of the combined deﬁ-
ciencies, complex I and IV deﬁciency were most commonly seen (20/30
cases) while combined complex I, III and IV deﬁciency, was present in
6/30 cases. In ﬁbroblasts, RCE analyses varied from normal in 4/10
[33%] to a single complex deﬁciency in 2/10 [20%], while a combined
complex deﬁciency was present in 4/10 [40%]. Also in this tissue, the
most commonly observed biochemical defect was a combined complex I
and IV deﬁciency.
3.5. Treatments
Various combinations of vitamin/anti-oxidant supplements (the
‘mitochondrial cocktail’) according to each institution clinical prac-
tice were administered. Of the 35 patients, 8 did not have any
treatment directed towards primary mitochondrial dysfunction and
for 2 information is unavailable. Supportive treatments, not directed
at primary mitochondrial dysfunction such as inotropes and tube
feeding, were not recorded. For the remaining patients, 14/25 [56%]
cases were commenced on L-carnitine, 17/25 [68%] on co-enzyme
Q10, 6/25 [24%] on vitamin C, 4/25 [16%] on vitamin E, 11/25
[44%] on riboﬂavin and 5/25 [20%] on thiamine which had no ap-
preciable eﬀect. Also, dichloroacetate was administered to 8/25
[32%] patients with the intent of lowering lactate levels. The keto-
genic diet was trialled in 5/22 [23%] patients, 3 of whom were
deemed unresponsive. Only one patient (patient 1) showed a clear
clinical improvement while in one other patient (patient 4) seizures
were initially better controlled after the start of the diet, but at
8 years, diﬀerent seizures types developed (drop attacks) and the diet
fat ratio was reduced. Visual deterioration occurred soon after onset
of ketogenic diet in patient no. 4 and in retrospect, this symptom was
unlikely related to the diet, but rather the result of a secondary
complication of MTO1 deﬁciency.
Table 2 (continued)
Patient no Nucleotide change Protein change Inheritance In silico prediction scores ExAC frequency
35 c.1949C > T
c.722C > T
p.Thr650Ile
p.Pro241Leu
Compound heterozygous CADD (33)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (33)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.000008241
Genotypes of 35 patients with MTO1 deﬁciency including inheritance pattern (homozygous versus compound heterozygotes), in silico prediction scores (CADD, SIFT and Polyphen) and
frequency observed in the ExAC database (http://exac.broadinstitute.org/).
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4. Discussion
The current series of 35 cases with bi-allelic mutations in MTO1,
which encodes a ubiquitously expressed enzyme necessary for opti-
mization of mtDNA-dependent protein synthesis, is to our knowledge
the largest to date. Review of their clinical features conﬁrmed as
hallmarks of this primary mitochondrial disease developmental/
cognitive impairment, lactic acidosis and complex IV deﬁciency
( ± other deﬁciencies) in muscle (http://www.proteinatlas.org/
ENSG00000135297-MTO1/tissue). Two patients are presented in
detail to illustrate the wide phenotypic spectrum of MTO1 deﬁ-
ciency, i.e. that a typical clinical presentation for this condition does
not exist and thus must be considered in patients with a variety of
features. Although early reports suggested that HCM at a young age
to be pathognomonic for MTO1 deﬁciency, HCM was absent in both
presented adolescent siblings. A further four cases of MTO1 deﬁ-
ciency without cardiomyopathy at ages 0.66 to 22 years, one pub-
lished and three unpublished, were identiﬁed in our review.
Together, these six cases prove that HCM is not a hallmark clinical
feature of this condition; in fact it was only reported as a presenting
feature in approximately half of cases (see Table 1). Although in
MTO1 deﬁciency the cardiomyopathy is usually hypertrophic, one
patient developed a dilated form (patient 12) which we recognize
may be a progression from HCM. As is common in rare diseases, the
phenotype of MTO1 deﬁciency appears more variable than initially
thought.
Other commonly occurring clinical features identiﬁed were
feeding diﬃculties, FTT, hypotonia and ocular pathology. Frequently
occurring biochemical characteristics include elevated plasma ala-
nine and mitochondrial markers in urine. This review also identiﬁed
a broad phenotypic spectrum for MTO1 deﬁciency from a severe,
rapidly progressive, ultimately fatal presentation in the neonatal
period to that of an 8-year-old presenting with ID, fatigability and
clumsiness and surviving to adulthood to that of a 19-year-old male
who presented at age 1 month with feeding diﬃculties, poor ocular
ﬁxation and HCM with reversal of many of his symptoms with by
Fig. 1. Protein sequence alignments of human MTO1 protein with orthologs. Sequence alignment of the human MTO1 protein with orthologs from Chlorobium tepidum, Escherichia coli,
Thermotoga maritima and Saccharomyces cerevisiae. The conserved amino acids are shaded and identiﬁed mutations in the cohort of 35 patients are denoted. The domain and motif
locations are depicted by coloured lines according to previously published work by Meyer et al. [21].
J.J. O'Byrne et al. Molecular Genetics and Metabolism 123 (2018) 28–42
37
1 year. At 19 years this patient has a recurrence of HCM but has
normal scholastic performance (Table 1).
The cohort of patients reviewed here further delineates the gen-
otype-phenotype relationship in MTO1 deﬁciency [7]. Consistent
with previous reports of an early-onset for the majority of mi-
tochondrial diseases involving the respiratory chain [22], almost
50% of our cohort presented in the ﬁrst two days of life and the re-
mainder presented by end of childhood, which is unsurprising for a
deﬁciency of an enzyme so ubiquitously expressed and involved in
such a fundamental process as posttranscriptional modiﬁcation of
speciﬁc mt-tRNAs [4,5]. Of those who presented in the ﬁrst two days
of life, 50% were deceased by two years suggesting a positive cor-
relation between early neonatal presentation and an unfavourable
prognosis, an observation supported by Martin et al. [23]. Im-
portantly, all of the patients who are compound heterozygous for a
missense variant and a frameshift variant had early presentation and
shorter than average survival time; none of the 35 cases had bi-allelic
truncating MTO1 alleles, suggesting that residual MTO1 protein
function is needed for survival in humans. An unexpected observa-
tion was that the sex ratio of those who are deceased is skewed to-
ward males, the cause of which is unexplained. To date cases have
been reported in 11 diﬀerent countries suggesting that MTO1 deﬁ-
ciency is probably a pan-ethnic condition (see Table 1).
The most frequent neurologic features of primary mitochondrial
disease are muscle weakness with hypotonia, followed by clinical or
imaging features of central neurological disease and cognitive im-
pairment/decline [22,24–26]. In the presented cohort, clinical pre-
sentation for the majority was during the neonatal period when
global developmental delay is diﬃcult to assess. Virtually all of the
patients for whom clinical information was available at a later age
did show an intellectual developmental disorder and/or other neu-
rologic impairment. Seizures were documented in approximately
one-third of cases while abnormalities of brain structure (including
anomalies of the claustrum and surrounding capsule, thalami, sub-
cortical white matter, cerebellar peduncles and the corpus callosum)
and an elevated lactate peak on spectroscopy were reported in more
than three-quarters of cases who underwent brain imaging. (Table 1
and Supplementary Table 1).
Interestingly, the phenotype diﬀers between MTO1 and other pro-
teins involved in post transcriptional modiﬁcation of speciﬁc mt-tRNAs,
such for example tRNA 5-methylaminomethyl-2-thiouridylate methyl-
transferase deﬁciency (TRMU) [27,28]. While TRMU mutations may
result in severe infantile hepatopathy or renal failure neither hepato-
pathy nor renal pathology are common features in MTO1 deﬁciency
with each observed in fewer than 10% of cases [29–31]. These may
however be features that will develop later in life.
Although the diagnosis of MTO1 deﬁciency may be suggested by the
presence of mitochondrial markers, such as plasma lactate, amino acids,
urinary mitochondrial markers and CSF lactate; these are not speciﬁc
(Table 3). Accordingly, the majority of cases were diagnosed by whole
or targeted exome sequencing rather than single gene tests. Respiratory
Chain Enzyme (RCE) analysis of muscle is a sensitive (though not
speciﬁc) test for MTO1 deﬁciency with enzyme deﬁciencies in all cases
known to date.
Given the role of MTO1 as an optimizer of mtDNA translation it is
not surprising that MTO1 mutations can be associated with impaired
mitochondrial protein synthesis and result in any combination of RC
deﬁciencies, from isolated complex IV deﬁciency to a combined
complex I and complex IV deﬁciency, the most commonly observed
biochemical signature. Complex I, III and IV deﬁciency, or isolated
deﬁciencies of complex I or complex IV were seen in a few patients.
This may be explained by the destination of the 13 mtDNA encoded
proteins; seven are core subunits of complex I, three of complex IV, two
of complex V (although this OXPHOS component cannot be easily
measured in frozen diagnostic muscle samples) and one of complex III;
complex II is entirely nuclear-encoded. Importantly the high number of
normal results in ﬁbroblasts indicates that normal RCE analysis in this
cell type do not exclude the possibility of a MTO1 defect. Given the lack
of speciﬁcity and invasiveness of some of these tests (muscle biopsy)
targeted WES approach may be the single most eﬀective diagnostic
approach to MTO1 deﬁciency which is illustrated by the two presented
cases.
Since the ﬁrst diagnosed case of MTO1 deﬁciency in 2012, many
cases have been trialled on several therapies such as L-carnitine,
coenzyme Q10, vitamin C, riboﬂavin, thiamine, dichloroacetate
(DCA) and/or vitamin E. Despite the use of multiple variations of this
“mitochondrial cocktail”, documented objective improvement was
rare. As MTO1 is a FAD moiety-containing enzyme, riboﬂavin sup-
plementation was investigated as a possible treatment without ob-
served success in either respiratory chain or ﬁbroblast oxygen con-
sumption analyses [6]. One such case where clinical and biochemical
improvement was noted was in patient no. 16 (Table 1). In this case
DCA is thought to have resulted in a marked improvement in LA
without side eﬀects reported. HCM also improved resulting in a
normal ECHO at 9 months and a normal scholastic performance at
19 years [6]. The authors recognise that DCA is expected to improve
LA without a clear eﬀect on seizures or neurological outcome [32].
Whether or not DCA had a direct positive eﬀect on HCM in patient
no. 16 is uncertain and the improvement may have been part of the
natural disease course in this case. One of the three patients with
MTO1 deﬁciency described by Martin et al. is also reported to have
improved on therapy. This report however should be viewed cau-
tiously as this patient also had vitamin B12 deﬁciency and secondary
hyperhomocystinemia; the improvement might have been due to
treatment of this deﬁciency rather than the MTO1 mitochondrio-
pathy as the lactic acidemia persisted [33]. Clinical improvement
was recorded in one of ﬁve patients trialled on ketogenic diets. At
age 19 months persistently high lactate levels (between 3 and
7 mmol/l) were present. After several months on a moderate keto-
genic diet the lactate levels normalized and they remain normal at
the time of publication. Improvement in motor development was
observed, as the patient learned to walk soon after starting the diet
and at 4 years of age he was able to walk several hundred meters
despite remaining ataxic. Speech development remained poor with
the expressive domain more severely aﬀected than receptive. His
initial mild cardiomyopathy resolved completely which the authors
recognize may have been the cause of his lactic acidemia and he
never developed seizures. Our female index initially also showed an
improvement on a ketogenic diet but subsequently her seizures
worsened. Thus the current data are insuﬃcient to draw conclusions
about the eﬀectiveness of the ketogenic diet; given the clinical im-
provement in the two patients described above, it may be worth
cautiously considering this treatment in MTO1 deﬁcient patients
with seizures, especially in light of the report of amelioration of the
defects in oxidative phosphorylation observed in MTO1 KO mice on a
ketogenic diet [11]. Of note Bartsakoulia et al suggests that N-acetyl-
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cysteine supplementation may have a beneﬁcial eﬀect on mi-
tochondrial translation in MTO1 deﬁcient ﬁbroblasts and this is a
future potential treatment [34].
The authors acknowledge several limitations in the study.
Although features such as LA and HCM seem to be the clinical hall-
mark of MTO1 deﬁciency, caution must be observed given the pos-
sible ascertainment bias introduced by the preselection based on the
presence of these symptoms. Also, because the ages of the patients
diﬀer with varied follow-up duration and quality, symptoms occur-
ring later in life may go unreported. An unexpected observation was
that the sex ratio of those who are deceased is skewed toward males.
This is unusual for a recessive condition and the authors recognize
that there is no obvious biological reason for this and it may be an
artefact of a small cohort. Although great care was used in compiling
the data kindly provided by clinicians and scientists in diﬀerent parts
of the world, the authors recognize a potential limitation in the study
was the lack of usage of uniform terminology for clinical and bio-
chemical signs and symptoms. We strongly advocate for use of
Human Phenotype Ontology (HPO) (http://human-phenotype-
ontology.github.io/) terms to enhance standardization, which will
facilitate and improve such studies in the future. Furthermore, in the
literature and lab reports, multiple transcript variants encoding at
least 3 diﬀerent MTO1 isoforms are used which has a potential for
confounding reporting and interpretation. Isoform a (NM_012123.3)
was chosen and in those papers where isoform b (NM_133645,
NP_598400) or c (NM_001123226, NP_001116698) was used, the
amino acid position was corrected according to isoform a, for con-
sistency in this study.
In summary, the mitochondrial disease knowledgebase is expanded
with this report on the largest cohort of MTO1 deﬁcient patients to date
and discussion about the phenotype (clinical and biochemical), geno-
type, natural history, outcomes and treatments. The features of MTO1
deﬁciency are non-speciﬁc which can make accurate diagnosis diﬃcult,
often requiring exome sequencing or gene panel analysis. We do re-
commend that physicians should consider this disease in patients with
LA, developmental/cognitive delay and other features of mitochondrial
disease. The report of three cases (the two presented siblings and case
no. 35) without cardiomyopathy at the adolescent age/early twenties
demonstrates that it is not an obligatory feature of the disease, which is
important for diﬀerential diagnostics. RCE analysis on muscle rather
than ﬁbroblasts is recommended as the latter can yield false negative
results. Once further MTO1 deﬁciency patients are diagnosed/identi-
ﬁed, development of phenotypic subgroups may become a possibility.
In general, early diagnosis is important for genetic counselling, prog-
nostication, screening for organ involvement, ending the diagnostic
odyssey and considering disease modifying interventions, such as the
ketogenic diet and, in the future, new therapies such as exosome-based
delivery [35].
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ymgme.2017.11.003.
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